Skip to main content
Journal cover image

Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease.

Publication ,  Journal Article
Lance, EI; Faulcon, LM; Fu, Z; Yang, J; Whyte-Stewart, D; Strouse, JJ; Barron-Casella, E; Jones, K; Van Eyk, JE; Casella, JF; Everett, AD
Published in: Proteomics Clin Appl
September 2021

PURPOSE: Sickle cell disease (SCD) is an inherited hemoglobinopathy that causes stroke and silent cerebral infarct (SCI). Our aim was to identify markers of brain injury in SCD. EXPERIMENTAL DESIGN: Plasma proteomes were analyzed using a sequential separation approach of hemoglobin (Hb) and top abundant plasma protein depletion, followed by reverse phase separation of intact proteins, trypsin digestion, and tandem mass spectrometry. We compared plasma proteomes of children with SCD with and without SCI in the Silent Cerebral Infarct Multi-Center Clinical Trial (SIT Trial) to age-matched, healthy non-SCD controls. RESULTS: From the SCD group, 1172 proteins were identified. Twenty-five percent (289/1172) were solely in the SCI group. Twenty-five proteins with enriched expression in the human brain were identified in the SCD group. Neurogranin (NRGN) was the most abundant brain-enriched protein in plasma of children with SCD. Using a NRGN sandwich immunoassay and SIT Trial samples, median NRGN levels were higher at study entry in children with SCD (0.28 ng/mL, N = 100) compared to control participants (0.12 ng/mL, N = 25, p < 0.0004). CONCLUSIONS AND CLINICAL RELEVANCE: NRGN levels are elevated in children with SCD. NRGN and other brain-enriched plasma proteins identified in plasma of children with SCD may provide biochemical evidence of neurological injury.

Duke Scholars

Published In

Proteomics Clin Appl

DOI

EISSN

1862-8354

Publication Date

September 2021

Volume

15

Issue

5

Start / End Page

e2100003

Location

Germany

Related Subject Headings

  • Neurogranin
  • Biochemistry & Molecular Biology
  • 3205 Medical biochemistry and metabolomics
  • 1101 Medical Biochemistry and Metabolomics
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lance, E. I., Faulcon, L. M., Fu, Z., Yang, J., Whyte-Stewart, D., Strouse, J. J., … Everett, A. D. (2021). Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease. Proteomics Clin Appl, 15(5), e2100003. https://doi.org/10.1002/prca.202100003
Lance, Eboni I., Lisa M. Faulcon, Zongming Fu, Jun Yang, Donna Whyte-Stewart, John J. Strouse, Emily Barron-Casella, et al. “Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease.Proteomics Clin Appl 15, no. 5 (September 2021): e2100003. https://doi.org/10.1002/prca.202100003.
Lance EI, Faulcon LM, Fu Z, Yang J, Whyte-Stewart D, Strouse JJ, et al. Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease. Proteomics Clin Appl. 2021 Sep;15(5):e2100003.
Lance, Eboni I., et al. “Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease.Proteomics Clin Appl, vol. 15, no. 5, Sept. 2021, p. e2100003. Pubmed, doi:10.1002/prca.202100003.
Lance EI, Faulcon LM, Fu Z, Yang J, Whyte-Stewart D, Strouse JJ, Barron-Casella E, Jones K, Van Eyk JE, Casella JF, Everett AD. Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease. Proteomics Clin Appl. 2021 Sep;15(5):e2100003.
Journal cover image

Published In

Proteomics Clin Appl

DOI

EISSN

1862-8354

Publication Date

September 2021

Volume

15

Issue

5

Start / End Page

e2100003

Location

Germany

Related Subject Headings

  • Neurogranin
  • Biochemistry & Molecular Biology
  • 3205 Medical biochemistry and metabolomics
  • 1101 Medical Biochemistry and Metabolomics